Genetics of Migraine - Is There any Progress?

E. Klimov, N. Kondratieva, A. Anuchina, K. Skorobogatykh, J. Azimova, A. Sergeev, Elena A Naumova, O. Rudko, Z. Kokaeva, A. Soboleva, V. Sobolev, G. Tabeeva
{"title":"Genetics of Migraine - Is There any Progress?","authors":"E. Klimov, N. Kondratieva, A. Anuchina, K. Skorobogatykh, J. Azimova, A. Sergeev, Elena A Naumova, O. Rudko, Z. Kokaeva, A. Soboleva, V. Sobolev, G. Tabeeva","doi":"10.15406/JNSK.2017.07.00245","DOIUrl":null,"url":null,"abstract":"Until now, the diagnosis of “migraine” is exclusively clinical, and any diagnostic tests are aimed only at excluding other causes of headache [4]. There are also problems with migraine treatment and although both traditional analgesics and specific anti-migraine products are available in the market, treatment of migraine patients is still not sufficiently effective. For example, specific anti-migraine agents (triptans) help control only two out of three attacks, and migraine prevention products are considered effective, if they reduce the frequency of attacks by 50% or more. The chronification of migraine attacks and the development of chronic daily headaches, occurring in 1% of patients per year [5], are a significant clinical problem. However, about 10% of migraine patients in the population and 40-60% of patients visiting specialized headache centers are resistant to standard therapy [6]. Treatment of such patients is the most expensive.","PeriodicalId":106839,"journal":{"name":"Journal of Neurology and Stroke","volume":"27 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2017-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurology and Stroke","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/JNSK.2017.07.00245","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Until now, the diagnosis of “migraine” is exclusively clinical, and any diagnostic tests are aimed only at excluding other causes of headache [4]. There are also problems with migraine treatment and although both traditional analgesics and specific anti-migraine products are available in the market, treatment of migraine patients is still not sufficiently effective. For example, specific anti-migraine agents (triptans) help control only two out of three attacks, and migraine prevention products are considered effective, if they reduce the frequency of attacks by 50% or more. The chronification of migraine attacks and the development of chronic daily headaches, occurring in 1% of patients per year [5], are a significant clinical problem. However, about 10% of migraine patients in the population and 40-60% of patients visiting specialized headache centers are resistant to standard therapy [6]. Treatment of such patients is the most expensive.
偏头痛的遗传学-有进展吗?
到目前为止,“偏头痛”的诊断完全是临床诊断,任何诊断测试的目的都只是为了排除头痛的其他原因[4]。偏头痛的治疗也存在问题,尽管市场上有传统的镇痛药和特定的抗偏头痛产品,但对偏头痛患者的治疗仍然不够有效。例如,特定的抗偏头痛药物(曲坦类药物)只能控制三分之二的发作,如果偏头痛预防产品能将发作频率减少50%或更多,则被认为是有效的。偏头痛发作的慢性化和慢性每日头痛的发展,每年发生在1%的患者中[5],是一个重要的临床问题。然而,人群中约10%的偏头痛患者和40-60%到专门头痛中心就诊的患者对标准治疗有耐药性[6]。这类病人的治疗是最昂贵的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信